Search

Your search keyword '"Llombart A"' showing total 220 results
Start Over Author "Llombart A" Journal annals of oncology
220 results on '"Llombart A"'

1. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

Author

Goetz, M.P., Toi, M., Huober, J., Sohn, J., Trédan, O., Park, I.H., Campone, M., Chen, S.-C., Manso, L.M., Paluch-Shimon, S., Freedman, O.C., O’Shaughnessy, J., Pivot, X., Tolaney, S.M., Hurvitz, S.A., Llombart-Cussac, A., André, V., Saha, A., van Hal, G., Shahir, A., Iwata, H., and Johnston, S.R.D.

Published
2024
Full Text
View/download PDF

2. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

Author

Villacampa, G., Tung, N.M., Pernas, S., Paré, L., Bueno-Muiño, C., Echavarría, I., López-Tarruella, S., Roche-Molina, M., del Monte-Millán, M., Marín-Aguilera, M., Brasó-Maristany, F., Waks, A.G., Pascual, T., Martínez-Sáez, O., Vivancos, A., Conte, P.F., Guarneri, V., Vittoria Dieci, M., Griguolo, G., Cortés, J., Llombart-Cussac, A., Muñoz, M., Vidal, M., Adamo, B., Wolff, A.C., DeMichele, A., Villagrasa, P., Parker, J.S., Perou, C.M., Fernandez-Martinez, A., Carey, L.A., Mittendorf, E.A., Martín, M., Prat, A., and Tolaney, S.M.

Published
2023
Full Text
View/download PDF

3. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Bachelot, T., Bouzid, K., Campone, M., Desmoulins, I., Coudert, B., Bondarenko, I., Nowecki, Z., Glogowska, I., Ciruelos Gil, E., Errihani, H., Dalenc, F., Ricci, F., Dieras, V., Kaufman, B., Paluch-Shimon, S., Wardley, A., Schneeweiss, A., Ferreira, A., Mano, M., Kalofonos, H., Andreetta, C., Puglisi, F., Montemurro, F., Barrett, S., Zhang, Q., Mavroudis, D., Matus, J., Villarreal Garza, C., Beato, C., Ismael, G., Hu, X., Abdel Azeem, H., Gaafar, R., Perrin, C., Kerbrat, P., Ettl, J., Paepke, S., Hitre, E., Lang, I., Trudeau, M., Verma, S., Li, H., Hoffmann, O., Aktas, B., Cariello, A., Cruciani, G., Tienghi, A., Tondini, C., Al-Twegieri, T., Loman, N., Laing, R., Miles, D., Brain, E., Fasching, P., Lux, M., Frassoldati, A., Aziz, Z., Salas, J., Streb, J., Krzemieniecki, K., Wronski, A., Garcia Garcia, J., Menjon Beltran, S., Cicin, I., Schmid, P., Gallagher, C., Turner, N., Tong, Z., Boer, K., Juhász, B., Horvath, Z., Bianchini, G., Gianni, L., Curigliano, G., Juarez Ramiro, A., Susnjar, S., Matos, E., Sevillano, E., Garcia Estevez, L., Gokmen, E., Uslu, R., Wildiers, H., Schutz, F., Cruz, M., Bourgeois, H., von Schumann, R., Stemmer, S., Dominguez, A., Morales-Vásques, F., Wojtukiewicz, M., Trifunovic, J., Echarri Gonzalez, M.J., Illarramendi Mañas, J., Martinez De Dueñas, E., Voitko, N., Hicks, J., Waters, S., Barrett-Lee, P., Wheatley, D., De Boer, R., Cocquyt, V., Jerusalem, G., Barrios, C., Panasci, L., Mattson, J., Tanner, M., Gozy, M., Vasilopoulos, G., Papandreou, C., Revesz, J., Battelli, N., Benedetti, G., Latini, L., Gridelli, C., Lazaro Leon, J., Alarcón Company, J., Arance Fernandez, A., Barnadas Molins, A., Calvo Plaza, I., Bratos, R., Gonzalez Martin, A., Izarzugaza Peron, Y., Klint, L., Kovalev, A., McCarthy, N., Yeo, B., Kee, D., Thomson, J., White, S., Greil, R., Wang, S., Artignan, X., Juhasz-Böess, I., Rody, A., Ngan, R., Dourleshter, F., Goldberg, H., Doni, L., Di Costanzo, F., Ferraù, F., Drobniene, M., Aleknavicius, E., Rashid, K., Costa, L., de la Cruz Merino, L., Garcia Saenz, J., López, R., Del Val Munoz, O., Ozyilkan, O., Azribi, F., Jaafar, H., Baird, R., Verrill, M., Beith, J., Petzer, A., Moreira de Andrade, J., Bernstein, V., Macpherson, N., Rayson, D., Saad Eldin, I., Achille, M., Augereau, P., Müller, V., Rasco, A., Evron, E., Katz, D., Berardi, R., Cascinu, S., De Censi, A., Gennari, A., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Van den Bosch, J., Kukulska, M., Kalinka, E., Alonso, J., Dalmau Portulas, E., Del Mar Gordon Santiago, M., Pelaez Fernandez, I., Aksoy, S., Altundag, K., Senol Coskun, H., Bozcuk, H., Shparyk, Y., Barraclough, L., Levitt, N., Panwar, U., Kelly, S., Rigg, A., Varughese, M., Castillo, C., Fein, L., Malik, L., Stuart-Harris, R., Singer, C., Stoeger, H., Samonigg, H., Feng, J., Cedeño, M., Ruohola, J., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Grischke, E.-M., Simon, E., Wagner, S., Koumakis, G., Papazisis, K., Ben Baruch, N., Fried, G., Geffen, D., Karminsky, N., Peretz, T., Cavanna, L., Pedrazzioli, P., Grasso, D., Ruggeri, E., D’Auria, G., Moscetti, L., Juozaityte, E., Rodriguez Cid, J., Roerdink, H., Siddiqi, N., Passos Coelho, J., Arcediano Del Amo, A., Garcia Garre, E., García Gonzalez, M., Garcia-Palomo Perez, A., Herenandez Perez, C., Lopez Alvarez, P., Lopez De Ceballos, M.H., Martínez Jañez, N., Mele Olive, M., McAdam, K., Perren, T., Dunn, G., Humphreys, A., Taylor, W., Vera, R., Kaen, L., Andel, J., Steger, G., De Grève, J., Huizing, M., Hegg, R., Joy, A., Kuruvilla, P., Sehdev, S., Smiljanic, S., Kütner, R., Alexandre, J., Grosjean, J., Laplaige, P., Largillier, R., Maes, P., Martin, P., Pottier, V., Christensen, B., Khandan, F., Lück, H.-J., Zahm, D.-M., Fountzilas, G., Karavasilis, V., Safra, T., Inbar, M., Ryvo, L., Bonetti, A., Seles, E., Giacobino, A., Chavarri Guerra, Y., de Jongh, F., van der Velden, A., van Warmerdam, L., Vrijaldenhoven, S., Smorenburg, C.H., Cavero, M., Andres Conejero, R., Oltra Ferrando, A., Redondo Sanchez, A., Ribelles Entrena, N., Saura Grau, S., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Butt, M., Joffe, J., Poole, C., Woodings, P., Chakraborti, P., Yordi, G., Woodward, N., Nobre, A., Luiz Amorim, G., Califaretti, N., Fox, S., Robidoux, A., Li, E., Li, N., Jiang, J., Soria, T., Padrik, P., Lahdenpera, O., Barletta, H., Dohollou, N., Genet, D., Prulhiere, K., Coeffic, D., Facchini, T., Vieillot, S., Catala, S., Teixeira, L., Hesse, T., Kühn, T., Ober, A., Repp, R., Schröder, W., Pectasides, D., Bodoky, G., Kahan, Z., Jiveliouk, I., Rosengarten, O., Rossi, V., Alabiso, O., Pérez Martínez, M., van de Wouw, A.J., Smok-Kalwat, J., Damasecno, M., Augusto, I., Sousa, G., Saadein, A., Abdelhafiez, N., Abulkhair, O., Antón Torres, A., Corbellas Aparicio, M., Llorente Domenech, R., Florián Jerico, J., Garcia Mata, J., Gil Raga, M., Galan Brotons, A., Llombart Cussac, A., Llorca Ferrandiz, C., Martinez Del Prado, P., Olier Garate, C., Rodriguez Sanchez, C., Sanchez Gomez, R., Santisteban Eslava, M., Soberino, J., Vidal Losada Garcia, M., Soto de Prado, D., Torrego Garcia, J., Vicente Rubio, E., Garcia, M., Murias Rosales, A., Granstam Björneklett, H., Narbe, U., Jafri, M., Rea, D., Newby, J., Jones, A., Westwell, S., Ring, A., Alonso, I., Rodríguez, R., Ciruelos, E., Peretz-Yablonski, T., Merot, J.-L., Trask, P., du Toit, Y., Pena-Murillo, C., Revelant, V., and Klingbiel, D.

Published
2021
Full Text
View/download PDF

4. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Author

Bouzid, Kamel, Campone, Mario, Coudert, Bruno, Nowecki, Zbigniew, Errihani, Hassan, Dalenc, Florence, Ferreira, Ana, Mano, Max, Ricci, Francesco, Kalofonos, Haralabos, Andreetta, Claudia, Montemurro, Filippo, Barrett, Sophie, Zhang, Qingyuan, Mavroudis, Dimitris, Matus, Juan, Beato, Carlos, Hu, Xichun, Gaafar, Rabab, Abdel Azeem, Hamdy, Perrin, Christophe, Ettl, Johannes, Lang, Istvan, Verma, Sunil, Li, Huiping, Brain, Etienne, Hoffmann, Oliver, Cariello, Anna, Tondini, Carlo, Altwegeiri, Taher, Loman, Niklas, Lux, Michael, Frassoldati, Antonio, Aziz, Zeba, Salas, Fernando, Streb, Joanna, Wronski, Andrzej, Menjón Beltrán, Salomón, Cicin, Irfan, Schmid, Peter, Laing, Robert, Tong, Zhongsheng, Boer, Katalin, Juhasz, Balazs, Gianni, Luca, Curigliano, Giuseppe, Juarez, Alejandro, Susnjar, Snezana, Matos, Erika, Uslu, Ruchan, Wildiers, Hans, Cruz, Marcelo, Bourgeois, Hugues, von Schumann, Raquel, Stemmer, Salomón, Vásquez, Flavia Morales, Dominguez, Adriana, Wojtukiewicz, Marek, Trifunovic, Jasna, Illarramendi, Jose Juan, Garcia, Laura, Peron, Yann Izarzugaza, Echarri, Maria Jose, Voitko, Natliia, Wheatley, Duncan, Waters, Simon, De Boer, Richard, Jerusalem, Guy, Cocquyt, Véronique, Barrios, Carlos, Panasci, Lawrence, Mattson, Johanna, Tanner, Minna, Gozy, Michel, Vasilopoulos, Georgios, Revesz, Janos, Latini, Luciano, Gridelli, Cesare, Lazaro, Jesus, Gonzalez, Antonio, Barnadas Molins, Agusti, Martinez, Eduardo, Alarcón, Jesús, Arance, Ana, Klint, Leif, Kovalyov, Oleksiy, Baird, Richard, Yeo, Belinda, McCarthy, Nicole, Greil, Richard, Wang, Shusen, Artignan, Xavier, Augereau, Paule, Juhasz-Boess, Ingolf, Ngan, Roger, Goldberg, Hadassah, Di Costanzo, Francesco, Ferraù, Francesco, Aleknavicius, Eduardas, Rashid, Kamran, Costa, Luís, Angel Garcia, Jose, de la Cruz, Luis Ruiz, López López, Rafael, Del Val, Olga, Ozyilkan, Ozgur, Azribi, Fathi, Verrill, Mark, Turner, Nicholas, Beith, Jane, Petzer, Andreas, Andrade, Jurandyr, Bernstein, Vanessa, Rayson, Daniel, Saad Eldin, Ibtessam, Achille, Mihaëla, Mueller, Volkmar, Gennari, Alessandra, Cascinu, Stefano, Ghosn, Marwan, El-Saghir, Nagi, Van den Bosch, Joan, Oosterkamp, Rianne, Kukulska, Monika, Pelaez, Ignacio, Hernandez, Carolina, del Mar Gordon, Maria, Dalmau, Elsa, Alonso, Jose Luis, Aksoy, Sercan, Coskun, Hasan Senol, Shparyk, Yaroslav, Varughese, Mohini, Panwar, Udaiveer, Barraclough, Lisa, Levitt, Nicola, Hicks, Jonathan, Rigg, Anna, Allen, Mark, Castillo, Cecila, Fein, Luis Enrique, Stuart-Harris, Robin, Singer, Christian, Stoeger, Herbert, Smiljanic, Sasha, Feng, Jifeng, Cedeño, Miguel, Berdah, Jean Francois, Orfeuvre, Hubert, Goncalves, Anthony, Grischke, Eva-Maria, Simon, Eike, Wagner, Steffen, Efremidou, Anna, Papazisis, Konstantinos, Evron, Ella, Inbar, Moshe, Baruch, Noa Ben, Geffen, David, Karminsky, Natalya, Ruggeri, Enzo Maria, Luigi, Cavanna, Grasso, Donatella, Juozaityte, Elona, Rafael Rodriguez Cid, Jeronimo, Roerdink, Henk, Siddiqi, Neelum, Passos Coelho, José Luís, Garre, Elisa Garcia, Garcia, Andres, Martínez Jañez, Noelia, Lopez Ceballos, Maria Helena, Mele, Mireia, García, María, Arcediano, Alberto, McAdam, Karen, Perren, Timothy, Taylor, Wendy, Humphreys, Alison, Vera, Raul, Kaen, Luis Alberto, Steger, Günther, Andel, Johannes, de Grève, Jacques, Huizing, Manon, Hegg, Roberto, Joy, Anil, Sehdev, Sandeep, Kütner, Riina, Ruohola, Johanna, Dohollou, Nadine, Grosjean, Jessica, Laplaige, Philippe, Largillier, Rémy, Martin, Philippe, Pottier, Virginie, Alexandre, Jerome, Christensen, Bernd, Zahm, Dirk-Michael, Khandan, Fariba, Lueck, Hans-Joachim, Fountzilas, Georgios, Fried, Georgeta, Giacobino, Alice, Bonetti, Andrea, Guerra, Yanin Chavarri, Van Warmerdam, Laurens, Van der Velden, Annette, Vrijaldenhoven, Suzan, de Jongh, Felix, Cavero, Milagros, Andres Conejero, Raquel, Murias, Adolfo, Saura, Salvador, Oltra, Amparo, Redondo, Andres, Ribelles, Nuria, Bachmeier, Kilian, Joffe, Johnathan, Chakraborti, Prabir, Beresford, Mark, Butt, Mohammad, Poole, Christopher, Yordi, Gassan, Woodward, Natasha, Amorim, Gilberto, Califaretti, Nadia, Fox, Susan, Robidoux, Andre, Li, NanLi, Li, Nenxiao, Jiang, Jun, Soria, Tannia, Padrik, Peeter, Saarni, Outi, Genet, Dominique, Catala, Stéphanie, Barletta, Hugues, Teixeira, Luis, Facchini, Thomas, Hesse, Tobias, Kühn, Thorsten, Ober, Angelika, Repp, Roland, Schroeder, Willibald, Pectasides, Dimitrios, Bodoky, Gyorgy, Kahan, Zsuzsanna, Jiveliouk, Irina, Rosengarten, Ora, Alabiso, Oscar, Perez, Mario, Van de Wouw, Yes, Smok-Kalwat, Jolanta, Damasceno, Margarida, Sousa, Gabriela, Abulkhair, Omalkhair, Antón Torres, Antonio, Martinez, Maria Purificación, Garcia Mata, Jesús, Jesús Florián Jerico, Marta Santisteban, Llombart, Antonio, Sanchez, Rosa, Torrego, Juan Carlos, Garate, Clara Olier, Rodriguez, Cesar, Llorente, Rosa, de Prado, Diego Soto, Cortés, Javier, Llorca, Cristina, Galán, Antonio, Viñas Villaro, Gemma, Narbe, Ulrik, Bjömeklett, Helena Granstam, Westwell, Sarah, Newby, Jackie, Jafri, Mariam, Rodríguez, Robinson, Alonso, Isabel, Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., Paluch-Shimon, S., Wardley, A., Merot, J.-L., du Toit, Y., Easton, V., Lindegger, N., and Miles, D.

Published
2019
Full Text
View/download PDF

5. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

Author

Nuciforo, P., Pascual, T., Cortés, J., Llombart-Cussac, A., Fasani, R., Paré, L., Oliveira, M., Galvan, P., Martínez, N., Bermejo, B., Vidal, M., Pernas, S., López, R., Muñoz, M., Garau, I., Manso, L., Alarcón, J., Martínez, E., Rodrik-Outmezguine, V., Brase, J.C., Villagrasa, P., Prat, A., and Holgado, E.

Published
2018
Full Text
View/download PDF

6. 262P Niraparib plus aromatase inhibitors (AI) for germinal mutated BRCA1/2 (gBRCAm) or homologous recombination-deficient (HRd), hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): LUZERN interim analysis

Author

Pimentel, I., primary, Lema Roso, L., additional, Ramos Vazquez, M., additional, García Saenz, J.Á., additional, Palacios-Ozores, P., additional, De la Haba Rodriguez, J., additional, Blanch, S., additional, Prat, A., additional, Ales Martínez, J.E., additional, Alba Conejo, E., additional, Balmaña, J., additional, Perez Garcia, J.M., additional, Sampayo-Cordero, M., additional, Malfettone, A., additional, Cortés, J., additional, and Llombart Cussac, A., additional

Published
2022
Full Text
View/download PDF

7. 271P Eribulin (E) plus endocrine therapy (ET) in patients (pts) with HR[+]/HER2[-] metastatic breast cancer (mBC) after progression on previous ET: The REVERT study

Author

Lopez Gonzalez, A., primary, Del Barco Berron, S., additional, Garau Llinas, I., additional, Galan Gramaje, M., additional, Castelo, B., additional, Cortes Salgado, A., additional, Sanchez-Rovira, P., additional, Martinez Bueno, A., additional, García, A., additional, Gener, P., additional, Mina, L., additional, Alcalá, D., additional, Sampayo-Cordero, M., additional, Cortés, J., additional, Perez Garcia, J.M., additional, Llombart Cussac, A., additional, and Lopez Miranda, E., additional

Published
2022
Full Text
View/download PDF

10. 280P Personalized treatment approaches with HER2DX in early HER2-positive breast cancer: A precision tool for treatment decision-making

Author

Céspedes, M. Tapia, Cussac, A. Llombart, Tebar, C., Liebana, S.M., Molina, A. Magro, Abad, L. Palomar, Martinez, M.T.M., Melia, C. Hernando, Iranzo, V., Pouptsis, A., Bertran, A. Santaballa, Torregrosa Maicas, M.D., Burgués, O., Cano, I. Garrido, Lluch-Hernandez, A., Gonzalez, P. Villagrasa, Prat, A., bermejo, B., and Cejalvo, J.M.

Published
2024
Full Text
View/download PDF

11. LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria

Author

de la Haba Rodriguez, J., Cortés, J., Di Cosimo, S., Blancas López-Barajas, I., Cortez Castedo, S.P., López, A., López-Miranda, E., Pla Juher, H., Albacar Miro, C.R., Ponce, J., Carañana Ballerini, V., Paris Bouzas, L., Valero Arbizu, M., Ruiz Borrego, M.R.B., Iranzo, V., Garrido, A., Alcalá-López, D., Mina, L., Garcia Mosquera, J.J., and Llombart Cussac, A.

Published
2024
Full Text
View/download PDF

13. 95P PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study

Author

Pascual, T., primary, Bermejo De Las Heras, B., additional, Martinez, N., additional, Oliveira, M., additional, Pernas Simon, S., additional, Lopez Lopez, R., additional, Ruiz Cabrero, I., additional, Alarcon, J.D., additional, Martinez De Dueñas, E., additional, Malon Gimenez, D., additional, Gonzalez Cao, M., additional, Manso Sanchez, L.M., additional, Morales Murillo, S., additional, Lopez de Ceballos, H., additional, Cortés, J., additional, Llombart Cussac, A., additional, and Prat, A., additional

Published
2022
Full Text
View/download PDF

14. 14P Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO

Author

Teng, N., primary, Dalby, M.J., additional, Kiu, R., additional, Robinson, T., additional, Gion Cortes, M., additional, Bermejo De Las Heras, B., additional, Perez Garcia, J.M., additional, Calvo-Martinez, L., additional, Prat, A., additional, Marquez Vazquez, R., additional, Ruiz Borrego, M., additional, de la Cruz, S., additional, Llombart Cussac, A., additional, Curigliano, G., additional, Schmid, P., additional, Mancino, M., additional, Hall, L., additional, Robinson, S., additional, Cortés, J., additional, and Malfettone, A., additional

Published
2022
Full Text
View/download PDF

15. 93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial

Author

Gebhart, G., primary, Keyaerts, M., additional, Guiot, T., additional, Flamen, P., additional, Ruiz Borrego, M., additional, Stradella, A., additional, Bermejo De Las Heras, B., additional, Escriva de Romani, S., additional, Calvo-Martinez, L., additional, Ribelles Entrena, N., additional, Martinez, N., additional, Albacar Miro, C.R., additional, Colleoni, M.A., additional, Atienza de Frutos, M., additional, Sampayo-Cordero, M., additional, Cortés, J., additional, Perez Garcia, J.M., additional, and Llombart Cussac, A., additional

Published
2022
Full Text
View/download PDF

16. 205TiP ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)

Author

Cortés Salgado, A., primary, Perez Garcia, J.M., additional, Cortez Castedo, S.P., additional, Gion Cortes, M., additional, Morales Murillo, S., additional, Blancas López-Barajas, I., additional, Blanch, S., additional, Calvo Plaza, I., additional, Diaz Fernandez, N., additional, Marmé, F., additional, Martinez Bueno, A., additional, Taberner Bonastre, M.T., additional, De Laurentiis, M., additional, Ruiz Borrego, M., additional, Schmid, P., additional, Guarneri, V., additional, Gligorov, J., additional, Sampayo-Cordero, M., additional, Llombart Cussac, A., additional, and Cortés, J., additional

Published
2022
Full Text
View/download PDF

17. 14P Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO

Author

N. Teng, M.J. Dalby, R. Kiu, T. Robinson, M. Gion Cortes, B. Bermejo De Las Heras, J.M. Perez Garcia, L. Calvo-Martinez, A. Prat, R. Marquez Vazquez, M. Ruiz Borrego, S. de la Cruz, A. Llombart Cussac, G. Curigliano, P. Schmid, M. Mancino, L. Hall, S. Robinson, J. Cortés, and A. Malfettone

Subjects
Oncology, Hematology
Published
2022

18. 262P Niraparib plus aromatase inhibitors (AI) for germinal mutated BRCA1/2 (gBRCAm) or homologous recombination-deficient (HRd), hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): LUZERN interim analysis

Author

I. Pimentel, L. Lema Roso, M. Ramos Vazquez, J.Á. García Saenz, P. Palacios-Ozores, J. De la Haba Rodriguez, S. Blanch, A. Prat, J.E. Ales Martínez, E. Alba Conejo, J. Balmaña, J.M. Perez Garcia, M. Sampayo-Cordero, A. Malfettone, J. Cortés, and A. Llombart Cussac

Subjects
Oncology, Hematology
Published
2022

20. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study

Author

Martin-Broto, J., Gutierrez, A., Garcia-del-Muro, X., Lopez-Guerrero, J.A., Martinez-Trufero, J., de Sande, L.M., Lainez, N., Maurel, J., De Juan, A., Losa, F., Andres, R., Casado, A., Tejido, P.G., Blanco, R., Carles, J., Bellmunt, J., Gomez-España, A., Ramos, R., Martinez-Serra, J., Llombart-Bosch, A., and Poveda, A.

Published
2010
Full Text
View/download PDF

21. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Miles, D., primary, Ciruelos, E., additional, Schneeweiss, A., additional, Puglisi, F., additional, Peretz-Yablonski, T., additional, Campone, M., additional, Bondarenko, I., additional, Nowecki, Z., additional, Errihani, H., additional, Paluch-Shimon, S., additional, Wardley, A., additional, Merot, J.-L., additional, Trask, P., additional, du Toit, Y., additional, Pena-Murillo, C., additional, Revelant, V., additional, Klingbiel, D., additional, Bachelot, T., additional, Bouzid, K., additional, Desmoulins, I., additional, Coudert, B., additional, Glogowska, I., additional, Ciruelos Gil, E., additional, Dalenc, F., additional, Ricci, F., additional, Dieras, V., additional, Kaufman, B., additional, Ferreira, A., additional, Mano, M., additional, Kalofonos, H., additional, Andreetta, C., additional, Montemurro, F., additional, Barrett, S., additional, Zhang, Q., additional, Mavroudis, D., additional, Matus, J., additional, Villarreal Garza, C., additional, Beato, C., additional, Ismael, G., additional, Hu, X., additional, Abdel Azeem, H., additional, Gaafar, R., additional, Perrin, C., additional, Kerbrat, P., additional, Ettl, J., additional, Paepke, S., additional, Hitre, E., additional, Lang, I., additional, Trudeau, M., additional, Verma, S., additional, Li, H., additional, Hoffmann, O., additional, Aktas, B., additional, Cariello, A., additional, Cruciani, G., additional, Tienghi, A., additional, Tondini, C., additional, Al-Twegieri, T., additional, Loman, N., additional, Laing, R., additional, Miles, D., additional, Brain, E., additional, Fasching, P., additional, Lux, M., additional, Frassoldati, A., additional, Aziz, Z., additional, Salas, J., additional, Streb, J., additional, Krzemieniecki, K., additional, Wronski, A., additional, Garcia Garcia, J., additional, Menjon Beltran, S., additional, Cicin, I., additional, Schmid, P., additional, Gallagher, C., additional, Turner, N., additional, Tong, Z., additional, Boer, K., additional, Juhász, B., additional, Horvath, Z., additional, Bianchini, G., additional, Gianni, L., additional, Curigliano, G., additional, Juarez Ramiro, A., additional, Susnjar, S., additional, Matos, E., additional, Sevillano, E., additional, Garcia Estevez, L., additional, Gokmen, E., additional, Uslu, R., additional, Wildiers, H., additional, Schutz, F., additional, Cruz, M., additional, Bourgeois, H., additional, von Schumann, R., additional, Stemmer, S., additional, Dominguez, A., additional, Morales-Vásques, F., additional, Wojtukiewicz, M., additional, Trifunovic, J., additional, Echarri Gonzalez, M.J., additional, Illarramendi Mañas, J., additional, Martinez De Dueñas, E., additional, Voitko, N., additional, Hicks, J., additional, Waters, S., additional, Barrett-Lee, P., additional, Wheatley, D., additional, De Boer, R., additional, Cocquyt, V., additional, Jerusalem, G., additional, Barrios, C., additional, Panasci, L., additional, Mattson, J., additional, Tanner, M., additional, Gozy, M., additional, Vasilopoulos, G., additional, Papandreou, C., additional, Revesz, J., additional, Battelli, N., additional, Benedetti, G., additional, Latini, L., additional, Gridelli, C., additional, Lazaro Leon, J., additional, Alarcón Company, J., additional, Arance Fernandez, A., additional, Barnadas Molins, A., additional, Calvo Plaza, I., additional, Bratos, R., additional, Gonzalez Martin, A., additional, Izarzugaza Peron, Y., additional, Klint, L., additional, Kovalev, A., additional, McCarthy, N., additional, Yeo, B., additional, Kee, D., additional, Thomson, J., additional, White, S., additional, Greil, R., additional, Wang, S., additional, Artignan, X., additional, Juhasz-Böess, I., additional, Rody, A., additional, Ngan, R., additional, Dourleshter, F., additional, Goldberg, H., additional, Doni, L., additional, Di Costanzo, F., additional, Ferraù, F., additional, Drobniene, M., additional, Aleknavicius, E., additional, Rashid, K., additional, Costa, L., additional, de la Cruz Merino, L., additional, Garcia Saenz, J., additional, López, R., additional, Del Val Munoz, O., additional, Ozyilkan, O., additional, Azribi, F., additional, Jaafar, H., additional, Baird, R., additional, Verrill, M., additional, Beith, J., additional, Petzer, A., additional, Moreira de Andrade, J., additional, Bernstein, V., additional, Macpherson, N., additional, Rayson, D., additional, Saad Eldin, I., additional, Achille, M., additional, Augereau, P., additional, Müller, V., additional, Rasco, A., additional, Evron, E., additional, Katz, D., additional, Berardi, R., additional, Cascinu, S., additional, De Censi, A., additional, Gennari, A., additional, El-Saghir, N., additional, Ghosn, M., additional, Oosterkamp, H.M., additional, Van den Bosch, J., additional, Kukulska, M., additional, Kalinka, E., additional, Alonso, J., additional, Dalmau Portulas, E., additional, Del Mar Gordon Santiago, M., additional, Pelaez Fernandez, I., additional, Aksoy, S., additional, Altundag, K., additional, Senol Coskun, H., additional, Bozcuk, H., additional, Shparyk, Y., additional, Barraclough, L., additional, Levitt, N., additional, Panwar, U., additional, Kelly, S., additional, Rigg, A., additional, Varughese, M., additional, Castillo, C., additional, Fein, L., additional, Malik, L., additional, Stuart-Harris, R., additional, Singer, C., additional, Stoeger, H., additional, Samonigg, H., additional, Feng, J., additional, Cedeño, M., additional, Ruohola, J., additional, Berdah, J.-F., additional, Goncalves, A., additional, Orfeuvre, H., additional, Grischke, E.-M., additional, Simon, E., additional, Wagner, S., additional, Koumakis, G., additional, Papazisis, K., additional, Ben Baruch, N., additional, Fried, G., additional, Geffen, D., additional, Karminsky, N., additional, Peretz, T., additional, Cavanna, L., additional, Pedrazzioli, P., additional, Grasso, D., additional, Ruggeri, E., additional, D’Auria, G., additional, Moscetti, L., additional, Juozaityte, E., additional, Rodriguez Cid, J., additional, Roerdink, H., additional, Siddiqi, N., additional, Passos Coelho, J., additional, Arcediano Del Amo, A., additional, Garcia Garre, E., additional, García Gonzalez, M., additional, Garcia-Palomo Perez, A., additional, Herenandez Perez, C., additional, Lopez Alvarez, P., additional, Lopez De Ceballos, M.H., additional, Martínez Jañez, N., additional, Mele Olive, M., additional, McAdam, K., additional, Perren, T., additional, Dunn, G., additional, Humphreys, A., additional, Taylor, W., additional, Vera, R., additional, Kaen, L., additional, Andel, J., additional, Steger, G., additional, De Grève, J., additional, Huizing, M., additional, Hegg, R., additional, Joy, A., additional, Kuruvilla, P., additional, Sehdev, S., additional, Smiljanic, S., additional, Kütner, R., additional, Alexandre, J., additional, Grosjean, J., additional, Laplaige, P., additional, Largillier, R., additional, Maes, P., additional, Martin, P., additional, Pottier, V., additional, Christensen, B., additional, Khandan, F., additional, Lück, H.-J., additional, Zahm, D.-M., additional, Fountzilas, G., additional, Karavasilis, V., additional, Safra, T., additional, Inbar, M., additional, Ryvo, L., additional, Bonetti, A., additional, Seles, E., additional, Giacobino, A., additional, Chavarri Guerra, Y., additional, de Jongh, F., additional, van der Velden, A., additional, van Warmerdam, L., additional, Vrijaldenhoven, S., additional, Smorenburg, C.H., additional, Cavero, M., additional, Andres Conejero, R., additional, Oltra Ferrando, A., additional, Redondo Sanchez, A., additional, Ribelles Entrena, N., additional, Saura Grau, S., additional, Viñas Vilaro, G., additional, Bachmeier, K., additional, Beresford, M., additional, Butt, M., additional, Joffe, J., additional, Poole, C., additional, Woodings, P., additional, Chakraborti, P., additional, Yordi, G., additional, Woodward, N., additional, Nobre, A., additional, Luiz Amorim, G., additional, Califaretti, N., additional, Fox, S., additional, Robidoux, A., additional, Li, E., additional, Li, N., additional, Jiang, J., additional, Soria, T., additional, Padrik, P., additional, Lahdenpera, O., additional, Barletta, H., additional, Dohollou, N., additional, Genet, D., additional, Prulhiere, K., additional, Coeffic, D., additional, Facchini, T., additional, Vieillot, S., additional, Catala, S., additional, Teixeira, L., additional, Hesse, T., additional, Kühn, T., additional, Ober, A., additional, Repp, R., additional, Schröder, W., additional, Pectasides, D., additional, Bodoky, G., additional, Kahan, Z., additional, Jiveliouk, I., additional, Rosengarten, O., additional, Rossi, V., additional, Alabiso, O., additional, Pérez Martínez, M., additional, van de Wouw, A.J., additional, Smok-Kalwat, J., additional, Damasecno, M., additional, Augusto, I., additional, Sousa, G., additional, Saadein, A., additional, Abdelhafiez, N., additional, Abulkhair, O., additional, Antón Torres, A., additional, Corbellas Aparicio, M., additional, Llorente Domenech, R., additional, Florián Jerico, J., additional, Garcia Mata, J., additional, Gil Raga, M., additional, Galan Brotons, A., additional, Llombart Cussac, A., additional, Llorca Ferrandiz, C., additional, Martinez Del Prado, P., additional, Olier Garate, C., additional, Rodriguez Sanchez, C., additional, Sanchez Gomez, R., additional, Santisteban Eslava, M., additional, Soberino, J., additional, Vidal Losada Garcia, M., additional, Soto de Prado, D., additional, Torrego Garcia, J., additional, Vicente Rubio, E., additional, Garcia, M., additional, Murias Rosales, A., additional, Granstam Björneklett, H., additional, Narbe, U., additional, Jafri, M., additional, Rea, D., additional, Newby, J., additional, Jones, A., additional, Westwell, S., additional, Ring, A., additional, Alonso, I., additional, and Rodríguez, R., additional

Published
2021
Full Text
View/download PDF

22. 56P Continuation treatment with immunotherapy beyond two years in patients with metastasic non-small cell lung cancer: Retrospective analysis of optimal duration treatment

Author

Pellicer Boigues, A.V., primary, Garde Noguera, J., additional, Garcia Sanchez, J., additional, Piera, N., additional, Fenollosa Sanz, T., additional, Llor Rodriguez, P., additional, Iranzo Barreira, J., additional, Riquelme Cabrera, P., additional, Fernandez Murga Chavanne, M.L., additional, and Llombart Cussac, A., additional

Published
2021
Full Text
View/download PDF

23. 330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH

Author

Vaz Batista, M., primary, Pérez-Garcia, J.M., additional, Llombart Cussac, A., additional, Cortez, P., additional, Ruiz Borrego, M., additional, De La Haba, J., additional, Cejalvo, J.M., additional, Racca, F., additional, Servitja, S., additional, Blanch, S., additional, Lema, L., additional, Galàn Garmaje, M., additional, Fernández-Abad, M., additional, Fernández, A., additional, Iranzo, V., additional, González-Santiago, S., additional, Gion, M., additional, Nave, M., additional, Cortés, J., additional, and Braga, S., additional

Published
2021
Full Text
View/download PDF

24. 123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer

Author

Schmid, P., primary, Bofill, F.J. Salvador, additional, Bermejo, B., additional, Phillips, M., additional, Wheatley, D., additional, Neus, F., additional, Schem, C., additional, Stradella, A., additional, Mele, M., additional, Salgado, A. Cortes, additional, Quiroga, V., additional, Torres, A. Antón, additional, Cussac, A. Llombart, additional, Zamora, E., additional, Viale, G., additional, Kuemmel, S., additional, Prendergast, A., additional, Mousa, K., additional, Gluz, O., additional, and Cortés, J., additional

Published
2021
Full Text
View/download PDF

25. 241P Abemaciclib plus fulvestrant in participants with HR+/HER2- advanced breast cancer: A pooled analysis of the endocrine therapy naïve (EN) participants in MONARCH 2

Author

Luis-Gonzalez Trujillo, J., primary, Escobar Gomez, M., additional, Sohn, J.H., additional, Im, Y-H., additional, Wang, H-C., additional, Llombart Cussac, A., additional, Zhang, W., additional, Haddad, N., additional, Wasserstrom, H., additional, van Hal, G., additional, and Sledge, G.W., additional

Published
2021
Full Text
View/download PDF

26. 336TiP Ipatasertib plus non-taxane chemotherapy for metastatic triple-negative breast cancer (TNBC): Pathfinder trial

Author

Llombart Cussac, A., primary, Soberino, J., additional, Gion, M., additional, Bermejo, B., additional, Martinez- Garcia, M., additional, Braga, S., additional, Cardoso, F., additional, Vieira, C., additional, Lopez-Miranda, E., additional, Sampayo, M., additional, Malfettone, A., additional, Cortés, J., additional, and Pérez-Garcia, J.M., additional

Published
2021
Full Text
View/download PDF

27. 93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial

Author

G. Gebhart, M. Keyaerts, T. Guiot, P. Flamen, M. Ruiz Borrego, A. Stradella, B. Bermejo De Las Heras, S. Escriva de Romani, L. Calvo-Martinez, N. Ribelles Entrena, N. Martinez, C.R. Albacar Miro, M.A. Colleoni, M. Atienza de Frutos, M. Sampayo-Cordero, J. Cortés, J.M. Perez Garcia, and A. Llombart Cussac

Subjects
Oncology, Hematology
Published
2022

28. 95P PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study

Author

T. Pascual, B. Bermejo De Las Heras, N. Martinez, M. Oliveira, S. Pernas Simon, R. Lopez Lopez, I. Ruiz Cabrero, J.D. Alarcon, E. Martinez De Dueñas, D. Malon Gimenez, M. Gonzalez Cao, L.M. Manso Sanchez, S. Morales Murillo, H. Lopez de Ceballos, J. Cortés, A. Llombart Cussac, and A. Prat

Subjects
Oncology, Hematology
Published
2022

29. 205TiP ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)

Author

A. Cortés Salgado, J.M. Perez Garcia, S.P. Cortez Castedo, M. Gion Cortes, S. Morales Murillo, I. Blancas López-Barajas, S. Blanch, I. Calvo Plaza, N. Diaz Fernandez, F. Marmé, A. Martinez Bueno, M.T. Taberner Bonastre, M. De Laurentiis, M. Ruiz Borrego, P. Schmid, V. Guarneri, J. Gligorov, M. Sampayo-Cordero, A. Llombart Cussac, and J. Cortés

Subjects
Oncology, Hematology
Published
2022

30. 129TiP Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR)[+]/HER2[–] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA

Author

Llombart Cussac, A., primary, Pérez-Garcia, J.M., additional, Blanch, S., additional, Tolosa, P., additional, Ruiz Borrego, M., additional, Gion Cortes, M., additional, Fernádez, A., additional, Urruticoechea, A., additional, Galve, E., additional, Cueva Banuelos, J.F., additional, Ponce, J., additional, Alonso, J.L., additional, Capelán, M., additional, Martínez, E., additional, Bermejo De Las Heras, B., additional, Rojas, B., additional, Martos, T., additional, López, A., additional, Gómez-Peralta, F., additional, and Cortés, J., additional

Published
2021
Full Text
View/download PDF

31. 330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH

Author

P. Cortez, M. Nave, Fabricio Racca, Jose Perez-Garcia, J de la Haba, M. Fernández-Abad, Sofia Braga, Santiago González-Santiago, M. Ruiz Borrego, J.M. Cejalvo, M. Galàn Garmaje, Antonio J. Fernández, S. Blanch, L. Lema, J. Cortés, M. Gion, M. Vaz Batista, A. Llombart Cussac, V. Iranzo, and Sonia Servitja

Subjects
Oncology, business.industry, Trastuzumab, Cancer research, Medicine, Hematology, business, medicine.disease, Metastatic breast cancer, medicine.drug
Published
2021

32. 241P Abemaciclib plus fulvestrant in participants with HR+/HER2- advanced breast cancer: A pooled analysis of the endocrine therapy naïve (EN) participants in MONARCH 2

Author

M. Escobar Gomez, Nadine Haddad, G. van Hal, H-C. Wang, H. Wasserstrom, Y-H. Im, George W. Sledge, J. Luis-Gonzalez Trujillo, Wei-Wei Zhang, Jung Ho Sohn, and A. Llombart Cussac

Subjects
Oncology, medicine.medical_specialty, Fulvestrant, business.industry, Advanced breast, Endocrine therapy, Cancer, Hematology, medicine.disease, chemistry.chemical_compound, Pooled analysis, chemistry, Internal medicine, medicine, business, Abemaciclib, medicine.drug
Published
2021

33. 123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer

Author

S. Kuemmel, Duncan Wheatley, Begoña Bermejo, F. Neus, Christian Schem, G. Viale, Agostina Stradella, J. Cortés, A. Llombart Cussac, Peter Schmid, F.J. Salvador Bofill, Aaron Prendergast, Esther Zamora, M. Phillips, Kelly Mousa, A. Anton Torres, Vanesa Quiroga, A. Cortes Salgado, O Gluz, and M Melé

Subjects
Oncology, Chemotherapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, Phases of clinical research, Hematology, Ipatasertib, Atezolizumab, Internal medicine, medicine, business, Triple-negative breast cancer
Published
2021

34. 165P Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response (pCR) in HER2-positive early breast cancer (EBC): A sub analysis of PHERGain trial

Author

Gion Cortes, M., Garcia Mosquera, J.J., Pérez-García, J.M., Peg Cámara, V., Guerrero, J.A., López-Montero, L., Mancino, M., Rodríguez Morató, J., Antonarelli, G., Fernández-Murga, L., Serrano García, L., Puglia, V., Llombart Cussac, A., and Cortés, J.

Published
2023
Full Text
View/download PDF

35. 150P Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial

Author

Llombart Cussac, A., Pérez-García, J.M., Pare Brunet, L., Villacampa Javierre, G., Brasó-Maristany, F., Gion Cortes, M., Schmid, P., Colleoni, M.A., Ruiz Borrego, M., Galván, P., Parker, J., Perou, C.M., Villagrasa Gonzalez, P., Guerrero, J.A., Sampayo-Cordero, M., Mancino, M., Prat, A., and Cortés, J.

Published
2023
Full Text
View/download PDF

36. 1764P Prevalence, severity and evolution of Coronavirus disease 19 (COVID-19) infection in cancer patients from Mediterranean population

Author

P. Llor Rodriguez, B. Honrubia Peris, J. Garde Noguera, T. Fenollosa Sanz, N. Piera Molons, A. Fernandez Do Nascimento, A.V. Pellicer Boigues, A. Albert Balaguer, J. García Sánchez, E. Cabrera Espinos, V. Carañana Ballerini, A. Llombart Cussac, M. D. C. Gomez Soler, and Maria L. Fernández-Murga

Subjects
medicine.medical_specialty, education.field_of_study, Bladder cancer, business.industry, Population, Cancer, Retrospective cohort study, Hematology, medicine.disease, Article, Oncology, Internal medicine, Intensive care, Medicine, Seroprevalence, Medical history, Risk factor, business, education
Abstract

Background: On March 11, 2020 World Health Organization (WHO) declared the global pandemic for Sars-Cov-2 Virus (COVID-19) Patients with cancer are generally more vulnerable to infections, systematic studies of diverse cohorts of patients with cancer affected by COVID-19 are needed Methods: Retrospective study of patients hospitalized with PCR+ for COVID-19 to assess the rate of cancer patients and describe clinical, pathological characteristics and evolution of their disease In addition, a transversal study of seroprevalence (IgG/IgM by ELISA-method) against Sars-Cov-2 is being carried out in patients undergoing active treatment Immunophenotype analysis will be performed for patients with IgG/IgM+ test and a cohort of patients with negative test that will be used as controls Results: 581 patients with mild to severe COVID-19 and PCR+ have been admitted at the Arnau Vilanova University Hospital in Valencia, Spain A total of 18 patients had medical history of cancer (3%) 72% were male and median age was 76 years Most frequent cancers were breast (16,7%), colon (16,7%) and bladder (16,7%) Fourteen had been treated for an early stage and were disease free at the time of the COVID-19 (83,3%) Three patients were on active systemic therapy: 2 chemotherapy (1 on neoadjuvant treatment for bladder cancer, 1 on chemo-radiotherapy for stage III NSCLC, and 1 with adjuvant Imatinib for GIST) One patient with advanced hepatocarcinoma was on palliative treatment Most frequent symptoms were dyspnoea (66,7%), cough (66,7%), fever (66,7%), asthenia (44,4%) and diarrhea (16,7%) Four patients (22,2%) required Intensive Care and six (33,3%) died Preliminary results of first 86 ambulatory patients on active treatment evaluated for seroprevalence against Sars-Cov-2 reveal a 0% of IgG or IgM antibodies Conclusions: Rate of cancer patients admitted in hospital with COVID-19 infection was 3% Cancer patients are more likely to be elderly and present comorbidities that increase COVID-19 infection risk, so whether cancer might be a risk factor itself remains controversial We plan to recruit 300 patients on oncologic treatment, our preliminary results show a 0% seroprevalence Final results will be communicated at ESMO meeting Legal entity responsible for the study: Javier Garde-Noguera Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest

Published
2020
Full Text
View/download PDF

37. 68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC

Author

Saji, S., primary, Cussac, A. Llombart, additional, Andre, F., additional, Robson, M.E., additional, Harbeck, N., additional, Schmid, P., additional, Cescon, D.W., additional, Ahn, J.S., additional, Nanda, R., additional, Fan, L., additional, Mejia, J.A., additional, Karantza, V., additional, Bardia, A., additional, and Rugo, H.S., additional

Published
2020
Full Text
View/download PDF

38. 45O Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2

Author

Huang, C-S., primary, Toi, M., additional, Im, Y-H., additional, Iwata, H., additional, Sohn, J., additional, Wang, H-C., additional, Masuda, N., additional, Im, S-A., additional, Lu, Y., additional, Haddad, N., additional, Sakaguchi, S., additional, Hurt, K., additional, Neven, P., additional, Llombart-Cussac, A., additional, and Sledge, G., additional

Published
2020
Full Text
View/download PDF

40. 56P Continuation treatment with immunotherapy beyond two years in patients with metastasic non-small cell lung cancer: Retrospective analysis of optimal duration treatment

Author

T. Fenollosa Sanz, Nuria Piera, J. Iranzo Barreira, J. García Sánchez, M.L. Fernandez Murga Chavanne, P. Riquelme Cabrera, A. Llombart Cussac, J. Garde Noguera, P. Llor Rodriguez, and A.V. Pellicer Boigues

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Hematology, Immunotherapy, medicine.disease, Internal medicine, Retrospective analysis, medicine, CONTINUATION TREATMENT, In patient, Duration treatment, Non small cell, Lung cancer, business
Published
2021

41. 336TiP Ipatasertib plus non-taxane chemotherapy for metastatic triple-negative breast cancer (TNBC): Pathfinder trial

Author

Elena López-Miranda, Begoña Bermejo, Fatima Cardoso, M. Gion, Andrea Malfettone, Sofia Braga, M. Martinez Garcia, Jesus Soberino, Miguel Sampayo, A. Llombart Cussac, Jose Perez-Garcia, J. Cortés, and Cláudia Vieira

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, Taxane, business.industry, medicine.medical_treatment, Internal medicine, medicine, Hematology, business, Ipatasertib, Triple-negative breast cancer
Published
2021

43. 45O Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2

Author

S-A. Im, Y-H. Im, Karla Hurt, Noriyuki Masuda, George W. Sledge, C-S Huang, Antonio Llombart-Cussac, Yi Lu, H-C. Wang, Sachi Sakaguchi, M. Toi, H. Iwata, Joohyuk Sohn, Nadine Haddad, and Patrick Neven

Subjects
Oncology, medicine.medical_specialty, Fulvestrant, business.industry, Advanced breast, Cancer, Hematology, medicine.disease, chemistry.chemical_compound, chemistry, Internal medicine, medicine, Overall survival, East Asia, business, Abemaciclib, medicine.drug
Published
2020

45. 356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009

Author

Rugo, H.S., primary, Cussac, A. Llombart, additional, André, F., additional, Robson, M., additional, Saji, S., additional, Harbeck, N., additional, Schmid, P., additional, Cescon, D.W., additional, Ahn, J. Seok, additional, Nanda, R., additional, Fan, L., additional, Mejia, J., additional, Karantza, V., additional, and Bardia, A., additional

Published
2020
Full Text
View/download PDF

46. 1933MO TransFAL: Establishment of clinical trial-matched luminal breast cancer patient-derived xenografts (PDX) for translational studies

Author

Palafox, M., primary, Mina, L., additional, Malfettone, A., additional, Monserrat, L., additional, Rodriguez, M.J., additional, Rodríguez, O., additional, Guzmán, M., additional, Grueso, J., additional, Scaltriti, M., additional, Miquel, T., additional, Saura, C., additional, Capelán, M., additional, Gil-Gil, M., additional, Llombart Cussac, A., additional, Cortés, J., additional, Perez Garcia, J.M., additional, Del Campo, M., additional, Bellet Ezquerra, M., additional, and Serra, V., additional

Published
2020
Full Text
View/download PDF

47. 1764P Prevalence, severity and evolution of Coronavirus disease 19 (COVID-19) infection in cancer patients from Mediterranean population

Author

Garde Noguera, J., primary, Fernandez-Murga, M.L., additional, Honrubia Peris, B., additional, García Sánchez, J., additional, Piera Molons, N., additional, Gomez Soler, M.D.C., additional, Fenollosa Sanz, T., additional, Llor Rodriguez, P., additional, Carañana Ballerini, V., additional, Cabrera Espinos, E., additional, Albert Balaguer, A., additional, Fernandez Do Nascimento, A., additional, Pellicer Boigues, A., additional, and Llombart Cussac, A., additional

Published
2020
Full Text
View/download PDF

48. 101P Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial

Author

Llombart Cussac, A., primary, Prat, A., additional, Pérez-García, J.M., additional, Mateos, J., additional, Pascual, T., additional, Escrivà-De-Romani, S., additional, Stradella, A., additional, Ruiz-Borrego, M., additional, Bermejo De Las Heras, B., additional, Keyaerts, M., additional, Sampayo-Cordero, M., additional, Malfettone, A., additional, Cortés, R., additional, Galván, P., additional, Cortés, J., additional, and Gebhart, G., additional

Published
2020
Full Text
View/download PDF

49. 39P Role of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxel

Author

Álvarez-López, I., primary, González, E., additional, Manso, L.M., additional, Alonso, J.L., additional, Cruz-Hernández, J.J., additional, Carañana Ballerini, V., additional, Gallegos, I., additional, Quindós Varela, M., additional, Illaramendi, J.J., additional, Vicente, E., additional, Ballesteros Garcia, A.I., additional, Ayala de la Pena, F., additional, Perelló, A., additional, Vidal, J., additional, and Llombart Cussac, A., additional

Published
2020
Full Text
View/download PDF

50. 8P Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)

Author

Griguolo, G., primary, Serna, G., additional, Pascual, T., additional, Fasani, R., additional, Chic, N., additional, Paré, L., additional, Pernas, S., additional, Muñoz, M., additional, Oliveira, M., additional, Vidal, M., additional, Llombart Cussac, A., additional, Cortés, J., additional, Galván, P., additional, Bermejo, B., additional, Martínez, N., additional, López, R., additional, Morales, S., additional, Villagrasa, P., additional, Prat, A., additional, and Nuciforo, P., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results